Public's Perception Of Clinical Trials Presented At Seminar Sponsored By inVentiv Clinical Trial Recruitment Solutions - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Public's Perception Of Clinical Trials Presented At Seminar Sponsored By inVentiv Clinical Trial Recruitment Solutions Results of CISCRP Study Provide New Insights Into How to Engage the Public and Patients


Public's Perception Of Clinical Trials Presented At Seminar Sponsored By inVentiv Clinical Trial Recruitment Solutions

Results of CISCRP Study Provide New Insights Into How to Engage the Public and Patients

PR Newswire

PRINCETON, N.J., June 2, 2014 /PRNewswire/ -- inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to accelerate trials, in collaboration with The Center for Information and Study on Clinical Research Participation (CISCRP) has released the results of research showing public perceptions of clinical trials has improved – good news for companies hoping to recruit for a trial.

The results of the global research conducted by CISCRP were released at a half-day, invitation-only seminar sponsored by iCTRS for pharmaceutical and biotechnology companies in Princeton, NJ. 

The forum, which drew dozens of industry leaders from top life sciences companies, was designed to help sponsor organizations improve volunteers' experience in clinical trials.

"Since the last assessment of the public's perception of, and experiences in, clinical trials eight years ago, we've seen marked improvements in public perceptions about clinical research and participation," said CISCRP's Founder and Board Chair Ken Getz.  "The study also identified a number of significant age-related and regional differences in knowledge and perspectives which suggest opportunities to improve public and patient engagement initiatives."

According to the CISCRP study, the percentage of people who learn of clinical research from family members is almost three times higher in Latin America than in North America. And, patients in the Asia-Pacific region are less than half as likely as patients in North America to continue participating in a clinical research study because they feel obligated to do so.

Jim Kremidas, Senior Vice President of Patient Recruitment at iCTRS and a member of the CISCRP Board of Advisors, discussed how a better understanding of the patient and caregiver perspective can improve patient recruitment and retention in trials.

"The basis for successfully engaging patients is understanding them," he maintained. "Through conducting behavioral research, we can gain insights into people's decision-making processes, motivational drivers and influencers - all of which inform the success of a study's outreach strategy and communication plan."

Kremidas presented case studies demonstrating how behavioral science has been used by progressive companies to both speed enrollment and improve patient retention in trials. By relying on behavioral data to guide message development, sponsors and CROs can engage prospective subjects by using the most effective language, content, creative angle, and channels.

Throughout the seminar attendees exchanged opinions and discussed ways to ensure that study volunteer motivations and needs are a central consideration in clinical research design and execution.

The CISCRP 2013 Perceptions and Insights Study gathered responses from nearly 6,000 patients and the public worldwide. The results are published in five reports, available for download from CISCRP at https://www.ciscrp.org/programs-events/research-and-studies/perceptions-and-insights/. The Center is a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media, and policymakers about clinical research and the role each party plays in the process. inVentiv Health is a proud financial supporter of CISCRP and an advocate of its mission.

More information on the discipline of using behavioral research to improve patient engagement, is available within a related white paper, "The Voice of the Patient: Using Behavioral Science to Engage Clinical Trial Participants".  This white paper can be downloaded by visiting http://www.inventivhealth-ictrs.com/newsroom/publication-library/.

About inVentiv Health

inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our clients' development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment.  inVentiv Health's clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties;  the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

 

SOURCE inVentiv Health

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here